This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Fasinumab is a monoclonal antibody targeting nerve growth factor which is under investigation for the treatment of chronic cancer and non-cancer pain.

Generic Name
Fasinumab
DrugBank Accession Number
DB12157
Background

Fasinumab is a human IgG1k monoclonal antibody targeted against nerve growth factor (NGF). It is currently under investigation for the treatment osteoarthritic pain1 and has demonstrated significantly greater pain relief and functional improvement as compared to standard therapy (i.e. NSAIDs and/or opioids) in this patient population.2

NGF was first discovered in the 1950s3 and was the first neurotrophic factor to be identified and biochemically characterized.4 It has since been recognized for its role in nociceptive signaling transduction and has thus become an attractive target in the treatment of chronic pain conditions.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Fasinumab
External IDs
  • REGN475

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

During embryonic development, nerve growth factor (NGF) binds to tropomyosin receptor kinase A receptor (TrkA) and the low-affinity p75 neurotrophin receptor (NTR) on developing neuronal cell surfaces, which activates signaling pathways involved in neuronal growth and survival.3 In adults, the primary role of NGF shifts towards influencing nociceptive signaling transduction by releasing inflammatory mediators and regulating ion channels or receptors.3,4

Fasinumab is a human IgG1k monoclonal antibody targeted against NGF,1 interrupting pain signaling pathways and thus alleviating pain and improving function in patients suffering from chronic pain conditions.

TargetActionsOrganism
ABeta-nerve growth factor
inhibitor
Humans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Fasinumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Fasinumab.
AducanumabThe risk or severity of adverse effects can be increased when Fasinumab is combined with Aducanumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fasinumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Fasinumab.
AmivantamabThe risk or severity of adverse effects can be increased when Fasinumab is combined with Amivantamab.
AnifrolumabThe risk or severity of adverse effects can be increased when Anifrolumab is combined with Fasinumab.
AnsuvimabThe risk or severity of adverse effects can be increased when Fasinumab is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Fasinumab.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Fasinumab.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
11T51Q3082
CAS number
1190239-42-9

References

General References
  1. Kaplon H, Reichert JM: Antibodies to watch in 2021. MAbs. 2021 Jan-Dec;13(1):1860476. doi: 10.1080/19420862.2020.1860476. [Article]
  2. Cao Z, Zhou J, Long Z, Li Y, Sun J, Luo Y, Wang W: Targeting nerve growth factor, a new option for treatment of osteoarthritis: a network meta-analysis of comparative efficacy and safety with traditional drugs. Aging (Albany NY). 2020 Dec 3;13(1):1051-1070. doi: 10.18632/aging.202232. Epub 2020 Dec 3. [Article]
  3. Bimonte S, Cascella M, Forte CA, Esposito G, Cuomo A: The Role of Anti-Nerve Growth Factor Monoclonal Antibodies in the Control of Chronic Cancer and Non-Cancer Pain. J Pain Res. 2021 Jun 28;14:1959-1967. doi: 10.2147/JPR.S302004. eCollection 2021. [Article]
  4. Kumar V, Mahal BA: NGF - the TrkA to successful pain treatment. J Pain Res. 2012;5:279-87. doi: 10.2147/JPR.S33408. Epub 2012 Aug 17. [Article]
PubChem Substance
347911291
Wikipedia
Fasinumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentOsteoarthritis in the Hip Joint / Osteoarthritis of the Knee2
3CompletedTreatmentOsteoarthritis of the Knee or Hip1
3TerminatedTreatmentChronic Lower Back Pain (CLBP) / Osteoarthritis (OA)1
2CompletedTreatmentOsteoarthritis in the Hip Joint / Osteoarthritis of the Knee1
2CompletedTreatmentSciatica1
2TerminatedDiagnosticOsteoarthritis in the Hip Joint / Osteoarthritis of the Knee1
2TerminatedTreatmentBack pain1
2TerminatedTreatmentUpper Abdominal Pain1
2WithdrawnTreatmentOsteoarthritis (OA)1
2, 3CompletedTreatmentBack Pain Lower Back1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Receptor signaling protein activity
Specific Function
Nerve growth factor is important for the development and maintenance of the sympathetic and sensory nervous systems. Extracellular ligand for the NTRK1 and NGFR receptors, activates cellular signal...
Gene Name
NGF
Uniprot ID
P01138
Uniprot Name
Beta-nerve growth factor
Molecular Weight
26958.53 Da
References
  1. Kaplon H, Reichert JM: Antibodies to watch in 2021. MAbs. 2021 Jan-Dec;13(1):1860476. doi: 10.1080/19420862.2020.1860476. [Article]
  2. Cao Z, Zhou J, Long Z, Li Y, Sun J, Luo Y, Wang W: Targeting nerve growth factor, a new option for treatment of osteoarthritis: a network meta-analysis of comparative efficacy and safety with traditional drugs. Aging (Albany NY). 2020 Dec 3;13(1):1051-1070. doi: 10.18632/aging.202232. Epub 2020 Dec 3. [Article]

Drug created at October 20, 2016 21:29 / Updated at November 11, 2021 15:59